CHRONIC PHASE CML WITH SOLE P190 (E1A2) BCR::ABL1: PRELIMINARY DATA FROM THE ITALIAN NETWORK/CML CAMPUS (SIE 2026) - Oct 6, 2026 - Abstract #C058; Pres time: Sep 22, 2026; 11:50 AM - 01:20 PM; Location: HALL 4; "Among the 6 pts not in MMR, 1 is receiving imatinib, 2 asciminib and 3 ponatinib. Chronic phase CML with isolated p190 is a rare and biologically heterogeneous entity: in our cohort, re- sults seem comparable to classical p210 CML, but higher rate of high ELTS score suggests a potential adverse prog- nostic role. Larger studies are needed to better define prog- nostic factors and optimize treatment approaches in this un- common CML subtype."
Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1 • ASXL1 • DNMT3A
|
|
S. P. Pascale1; R. Nuccorini1; R. Latagliata2; M. Tribelli3; L. De Carolis4; M. Annunziata5; D. Rapezzi6; F. Muriano7; A. Maggi8; D. Cattaneo9; M. D'Adda10; A. Sicuranza11; M. Bonifacio12; U. Markovic13; D. Facchinelli14; E. Abruzzese15; S. Russo16; G. Binotto17; G. Spinosa18; A. Amendola1; I. Chitarrelli1; N. Filardi1; A. Matturro1; D. Vertone1; M. Pizzuti1; M. Cimminiello1
|